Premium
Urinary thymine dimers and 8‐oxo‐2′‐deoxyguanosine in psoriasis
Author(s) -
Ahmad Jabeen,
Cooke Marcus S.,
Hussieni Amina,
Evans Mark D.,
Patel Kayuri,
Burd Robert M.,
Bleiker Tanya O.,
Hutchinson Peter E.,
Lunec Joseph
Publication year - 1999
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(99)01402-7
Subject(s) - psoriasis , urinary system , deoxyguanosine , thymine , dermatology , urine , medicine , dna , chemistry , biochemistry , oxidative stress
Psoralen in conjunction with UVA (PUVA) is perhaps the most effective treatment for psoriasis. It is, however, a risk factor for skin cancer in these patients and there is a need to develop non‐invasive assays reflective of treatment‐induced DNA damage. We report here the assessment of two important lesions, thymine dimer (T〈〉T) and 8‐oxo‐2′‐deoxyguanosine (8‐OHdG), in the urine of psoriasis patients. It was found that, once corrected for urine concentration, the psoriatic group had significantly higher ( P <0.0001) urinary levels of thymine dimers compared to the control group. No significant differences in urinary 8‐OHdG levels were noted between the psoriatic, atopic dermatitis and control groups. Therefore biomonitoring of therapy from the very start with this simple and non‐invasive assay could perhaps be an effective measure of the risk involved with the treatment allowing optimization for minimal‐risk therapy.